Get the Stockscreener App
30.13
1.93%
0.57
Pre-market:
28.94
-1.19
-3.95%
Veracyte Inc stock is traded at $30.13, with a volume of 805.66K.
It is up +1.93% in the last 24 hours and down -13.32% over the past month.
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). In addition, its Percepta Nasal Swab test is being run in CLIA labs in support of clinical studies.
See More
Previous Close:
$29.56
Open:
$29
24h Volume:
805.66K
Relative Volume:
0.94
Market Cap:
$2.35B
Revenue:
$399.58M
Net Income/Loss:
$-54.04M
P/E Ratio:
-40.17
EPS:
-0.75
Net Cash Flow:
$40.13M
1W Performance:
-2.96%
1M Performance:
-13.32%
6M Performance:
-10.84%
1Y Performance:
+46.90%
1-Day Range:
$28.65
$30.86
1-Week Range:
$28.52
$31.83
52-Week Range:
$18.61
$47.32
Veracyte Inc Stock (VCYT) Company Profile
Name
Veracyte Inc
Sector
Industry
Phone
(650) 243-6300
Address
6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare VCYT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VCYT
Veracyte Inc
|
30.13 | 2.35B | 399.58M | -54.04M | 40.13M | -0.75 |
|
TMO
Thermo Fisher Scientific Inc
|
489.06 | 182.21B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
205.16 | 143.37B | 23.88B | 3.90B | 5.30B | 5.28 |
|
IDXX
Idexx Laboratories Inc
|
426.25 | 33.92B | 3.90B | 887.87M | 798.08M | 10.67 |
|
A
Agilent Technologies Inc
|
115.99 | 33.08B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
174.37 | 30.19B | 15.41B | 1.37B | 2.11B | 7.50 |
Veracyte Inc Stock (VCYT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-20-25 | Initiated | Craig Hallum | Buy |
| Dec-05-24 | Downgrade | Goldman | Buy → Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-16-24 | Initiated | UBS | Buy |
| Oct-10-24 | Initiated | Guggenheim | Buy |
| Feb-23-24 | Reiterated | Needham | Buy |
| Jan-18-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Jan-07-22 | Initiated | Stephens | Overweight |
| Nov-18-21 | Resumed | Goldman | Buy |
| Jun-15-21 | Initiated | Raymond James | Outperform |
| Feb-18-21 | Resumed | Needham | Buy |
| Jan-28-21 | Initiated | Truist | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Sep-09-20 | Initiated | Morgan Stanley | Underweight |
| Jul-31-19 | Initiated | Lake Street | Buy |
| Jul-02-19 | Initiated | Needham | Buy |
| Nov-29-18 | Downgrade | Janney | Buy → Neutral |
| Oct-31-18 | Upgrade | Janney | Neutral → Buy |
| Nov-07-17 | Downgrade | Janney | Buy → Neutral |
| Nov-07-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Aug-31-17 | Resumed | BTIG Research | Buy |
| Nov-14-16 | Resumed | Leerink Partners | Outperform |
| Dec-18-15 | Initiated | Cantor Fitzgerald | Buy |
| Jun-11-15 | Reiterated | Leerink Partners | Outperform |
| Nov-26-13 | Initiated | William Blair | Outperform |
View All
Veracyte Inc Stock (VCYT) Latest News
Veracyte (VCYT) Introduces AI-Powered Cancer Detection – Faster and More Accurate Than Ever! - Insider Monkey
9 AI News and Ratings on Investors’ Radar - Insider Monkey
Craig-Hallum bullish on Veracyte, initiates with a Buy - MSN
Veracyte (VCYT) Up 0.7% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Wall Street Analysts Believe Veracyte (VCYT) Could Rally 35.05%: Here's is How to Trade - Yahoo
New Data Demonstrate Accuracy of Veracyte’s Whole-Genome Sequencing-Based MRD Testing Platform for Muscle-Invasive Bladder Cancer - 01net
Veracyte Cancer Diagnostic Platform Shows Higher Specificity Than Blood Tests - Marketscreener.com
Veracyte (VCYT) Shares Cross Above 200 DMA - Nasdaq
Veracyte says new data demonstrate accuracy of WGS-based platform - TipRanks
New Data Demonstrate Accuracy Of Veracyte's Whole-Genome Sequencing-Based Mrd Testing Platform For Muscle-Invasive Bladder Cancer - Marketscreener.com
5 Analysts Assess Veracyte: What You Need To Know - Benzinga
Craig-Hallum initiates Veracyte stock with Buy, sets $45 target By Investing.com - Investing.com South Africa
Craig-Hallum initiates Veracyte stock with Buy, sets $45 target - Investing.com India
Craig-Hallum Initiates Veracyte at Buy With $45 Price Target -March 20, 2025 at 07:28 am EDT - Marketscreener.com
Veracyte Announces Eight Abstracts Highlighting Performance and Clinical Utility of Its Decipher and MRD Tests in Urologic Cancers To Be Presented at EAU25 - BioSpace
Veracyte's Decipher, MRD tests highlights to be presented at EAU25 -March 19, 2025 at 05:05 pm EDT - Marketscreener.com
Veracyte's Cancer Detection Tests Prove Powerful in Major Clinical StudiesNew Product Coming - StockTitan
Veracyte Stock Surges 45.6% in a Year: What's Driving the Rally? - Yahoo Finance
Veracyte’s chief commercial officer John Leite sells $234,629 in stock By Investing.com - Investing.com Canada
Veracyte’s chief commercial officer John Leite sells $234,629 in stock - Investing.com
Veracyte (VCYT) Surged on Reporting Strong Earnings - Insider Monkey
Veracyte Inc to Host Earnings Call - ACCESS Newswire
Shareholders Can Be Confident That Veracyte's (NASDAQ:VCYT) Earnings Are High Quality - Simply Wall St
29,779 Shares in Veracyte, Inc. (NASDAQ:VCYT) Purchased by Proficio Capital Partners LLC - Defense World
Veracyte at Raymond James Conference: Strategic Expansion and Growth By Investing.com - Investing.com Australia
Veracyte at Raymond James Conference: Strategic Expansion and Growth - Investing.com India
Insider Sell: Phillip Febbo Sells Shares of Veracyte Inc (VCYT) - GuruFocus.com
Principal Financial Group Inc. Has $1.29 Million Stock Holdings in Veracyte, Inc. (NASDAQ:VCYT) - Defense World
Veracyte Full Year 2024 Earnings: EPS Misses Expectations - Yahoo Finance
Veracyte, Inc. (NASDAQ:VCYT) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough - Simply Wall St
Veracyte, Inc. (NASDAQ:VCYT) Shares Sold by Truist Financial Corp - Defense World
Veracyte's (NASDAQ:VCYT) Performance Is Even Better Than Its Earnings Suggest - Yahoo Finance
Veracyte (NASDAQ:VCYT) Stock Price Expected to Rise, UBS Group Analyst Says - MarketBeat
Veracyte (NASDAQ:VCYT) Given Buy Rating at Needham & Company LLC - MarketBeat
Decoding Veracyte Inc (VCYT): A Strategic SWOT Insight - GuruFocus
ARK Investment Management LLC Reduces Holdings in Veracyte, Inc. (NASDAQ:VCYT) - MarketBeat
Veracyte (NASDAQ:VCYT) Trading 9.9% Higher on Analyst Upgrade - MarketBeat
Guggenheim Reaffirms Buy Rating for Veracyte (NASDAQ:VCYT) - MarketBeat
Phocas Financial Corp. Reduces Stake in Veracyte, Inc. (NASDAQ:VCYT) - MarketBeat
Veracyte (NASDAQ:VCYT) Shares Gap Down Following Weak Earnings - MarketBeat
VERACYTE, INC. SEC 10-K Report - TradingView
Rhumbline Advisers Purchases 675 Shares of Veracyte, Inc. (NASDAQ:VCYT) - Defense World
StockNews.com Downgrades Veracyte (NASDAQ:VCYT) to Hold - Defense World
Veracyte (NASDAQ:VCYT) Cut to "Hold" at StockNews.com - MarketBeat
Investor Network: Veracyte Inc to Host Earnings Call - ACCESS Newswire
Veracyte Inc Stock (VCYT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.78%
1.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):